Who are anti-CD25 rhMAb's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anti-cd25-rhmab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

anti-CD25 rhMAb — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

anti-CD25 rhMAb (anti-CD25 rhMAb) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD25 antagonist monoclonal antibody. Area: Immunology.

marketed CD25 antagonist monoclonal antibody CD25 (IL-2 receptor alpha chain) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

anti-CD25 rhMAb (anti-CD25 rhMAb) — Peking University People's Hospital. This recombinant humanized monoclonal antibody binds to CD25 (IL-2 receptor alpha chain) on activated T cells, blocking interleukin-2 signaling and suppressing T cell proliferation and activation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
anti-CD25 rhMAb TARGET	anti-CD25 rhMAb	Peking University People's Hospital	marketed	CD25 antagonist monoclonal antibody	CD25 (IL-2 receptor alpha chain)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD25 antagonist monoclonal antibody class)

Peking University People's Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). anti-CD25 rhMAb — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-cd25-rhmab. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing